Voyager Medical Research

Voyager Medical Research is developing proprietary polymers that are designed specifically to help prevent complications. Its first product, Voyager Surgical Suture (VSS), addresses the post-surgical complication of Incisional Hernia that is effecting up to 20% of patients undergoing a Laparotomy, leading to 5.3% mortality. ACE Surgical Suture, is a monofilament, absorbable surgical suture, intended for abdominal wall closure. The product is based on a co-polymer that was designed and validated in over 6 years of research at the Institute of Chemistry of the Hebrew University. ACE is composed of PPCA which is a unique co-polymer comprising Poly(Propylene Oxide) and Poly(Caprolactone) blocks, being chained extended with a diisocyanate (Hexamatheylene diisocyanate). Unlike competitor products that only provide 8 weeks of abdominal wall support, ACE offers as much as 5-6 months of support, enough to enable healing even for the most immune-suppressed patients.

Voyager Medical Research has raised $1.5M in total funding across 1 rounds. The company is currently at the Seed stage. Key investors include Israel Innovation Authority.

Voyager Medical Research was founded in 2015 by Daniel Cohn (Co-founder), Ariel Halevy (Medical Director).

Voyager Medical Research operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Biomaterials & Tissue Engineering, with core technologies in Materials & Substances, Polymers. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Voyager Medical Research is based in Rosh Pina St 11, Petah Tikva, Israel, Center District.